IZERVAY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Izervay, and what generic alternatives are available?
Izervay is a drug marketed by Astellas and is included in one NDA. There are eight patents protecting this drug.
This drug has one hundred patent family members in twenty-seven countries.
The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this compound. Additional details are available on the avacincaptad pegol sodium profile page.
DrugPatentWatch® Generic Entry Outlook for Izervay
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 14, 2025. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for IZERVAY
International Patents: | 100 |
US Patents: | 8 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Drug Prices: | Drug price information for IZERVAY |
What excipients (inactive ingredients) are in IZERVAY? | IZERVAY excipients list |
DailyMed Link: | IZERVAY at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for IZERVAY
Generic Entry Date for IZERVAY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVITREAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for IZERVAY
Drug Class | Complement Inhibitor |
Mechanism of Action | Complement Inhibitors |
US Patents and Regulatory Information for IZERVAY
IZERVAY is protected by eight US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of IZERVAY is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting IZERVAY
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for IZERVAY
When does loss-of-exclusivity occur for IZERVAY?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 06214437
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0607002
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 97889
Estimated Expiration: ⤷ Sign Up
Patent: 97900
Estimated Expiration: ⤷ Sign Up
Patent: 92874
Estimated Expiration: ⤷ Sign Up
Patent: 24030
Estimated Expiration: ⤷ Sign Up
China
Patent: 1155822
Estimated Expiration: ⤷ Sign Up
Patent: 3352037
Estimated Expiration: ⤷ Sign Up
Patent: 4404046
Estimated Expiration: ⤷ Sign Up
Patent: 8148840
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering IZERVAY around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 101374931 | ⤷ Sign Up | |
Eurasian Patent Organization | 201690212 | СПОСОБЫ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ОФТАЛЬМОЛОГИЧЕСКИХ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ | ⤷ Sign Up |
Australia | 2014286996 | Methods for treating or preventing ophthalmological conditions | ⤷ Sign Up |
Australia | 2006214437 | Aptamer therapeutics useful in the treatment of complement-related disorders | ⤷ Sign Up |
China | 105431204 | Methods for treating or preventing ophthalmological conditions | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |